

# RESAntiPath

TARPSWG – R2006

Study Period: January 1<sup>st</sup> 2017 – January 31<sup>st</sup> 2020

Specific dataset (not included in RESAR):

- None

Deadline for data transfer to Milan: **June 2021**

## ACTIONS:

- Activate DTA and join Framework Agreement (if not already done)
- DTA will be circulated in May 2021



## 1. STUDY TITLE

***ANTICIPATED ORGANS RESECTION AND PATHOLOGIC INFILTRATION - RESAntiPath***

## 2. PRINCIPAL INVESTIGATOR

PI            Marco Fiore, Milan  
Co-PI       Dirk Strauss, London

## 3. STATUS

**Open** to opt in for those who recruited between 2017 and 2020

## 4. COLLABORATIVE

19 centers opted in

### PRIMARY OUTCOME

- Rate and type of microscopic organ invasion according to
  - Histotype
  - LPS subtype

### SECONDARY OUTCOMES

- Type of organ resected according to
  - Histotype
  - Tumor Size
- Predictive value of (surgeon's) radiology assessment

TARPSWG- R2006 RESAntiPath



Institution				City				Framework Agreement			
1	Queen Elizabeth Hospital Birmingham	Birmingham	29-ott-20	11	Candiolo Cancer Institute	Candiolo	To be done				
2	Peter MacCallum Cancer Center	Melbourne	29-ott-20	12	Netherlands Cancer Institute	Amsterdam	To be done				
3	The Ottawa Hospital	Ottawa	29-ott-20	13	Mayo Clinic	Jacksonville	To be done				
4	The Ohio State University	Columbus	29-ott-20	14	Ludwig Maximilian University	Munich	To be done				
5	Leiden University Medical Center	Leiden	To be done	15	Moffitt Cancer Center	Tampa	To be done				
6	DFCI-BWH	Boston	29-ott-20	16	Tel-Aviv Sourasky Medical Center	Tel-Aviv	To be done				
7	NCC Tokyo	Tokyo	To be done	17	Royal Prince Alfred Hospital	Sydney	To be done				
8	Royal Marsden Hospital	London	To be done	18	Hospital San Pau	Barcelonaa	To be done				
9	Winship Cancer Institute, Emory University	Atlanta	To be done	19	Fondazione IRCCS Istituto Nazionale dei Tumori	Milano	29-ott-20				
10	Campus Biomedico	Roma	To be done								

Contacts  
marco.fiore@istitutotumori.mi.it